Imperial College London Featured PhD Programmes
University College London Featured PhD Programmes
Sheffield Hallam University Featured PhD Programmes
Imperial College London Featured PhD Programmes
Cardiff University Featured PhD Programmes

Pre-clinical investigations of POLQ inhibitors

Project Description

The aim of our research is to improve radiotherapy for cancer patients by making tumour cells more sensitive to radiation without affecting the sensitivity of normal cells. This would achieve greater tumour control without exacerbating side effects from damage to the adjacent tissues.

We have previously identified that depletion of DNA polymerase theta (POLQ) makes tumour cells more sensitive to radiation. POLQ is a DNA repair polymerase that plays a role in micro-homology mediated end-joining (MMEJ), an alternative DNA double-strand break repair pathway. POLQ is frequently overexpressed in many cancer types and this has been shown to be associated with adverse clinical outcomes. Importantly, POLQ has low or absent expression in most normal tissues and therefore represents an ideal tumour-specific radiosensitisation target. We established a drug development programme to make inhibitors against POLQ, which was subsequently spun-out into a new company (Artios).

In collaboration with Artios, we are testing specific POLQ inhibitors and have shown that they radiosensitise tumour cells but not normal cells. Through POLQ inhibition, tumour cells are less able to repair their radiation-induced DNA double strand breaks and thus more likely to die after radiotherapy.

This project aims to explore the most effective ways in which POLQ inhibitors can be applied clinically as a radiosensitising agent, exploring separate clinically relevant aspects. This will include exploring development of resistance to POLQ inhibition and assess the effect of POLQ inhibitors in hypoxia, a common feature of solid tumours that imparts resistance to radiotherapy. We also hypothesise that POLQ inhibition in combination with radiation will increase cGAS-STING pathway activity, a key activator of immune stimulatory signalling. The project will therefore also investigate whether POLQ inhibitors can improve the efficacy of immune checkpoint inhibitors, an effective cancer treatment, but which still requires optimisation to benefit a larger proportion of patients.

Having hosted seven DPhil students over the last nine years, our group has an excellent track record in supervising DPhil candidates. Aside from supervision from the principal investigator, the successful candidate will be thoroughly trained and closely mentored by experienced post-doctoral scientists in the group. Our group is very experienced in molecular biological and tissue culture techniques, high-throughput screening, epifluorescence and confocal microscopy, including high content and live cell imaging, and flow cytometry. We complement laboratory studies with in vivo experiments using state-of-the-art pre-clinical radiation and imaging techniques and have set up two clinical trials based on findings in our lab.

This project offers a unique opportunity to be at the forefront of drug development and to gain a wide range of experimental and transferable skills.

Our close collaboration with Artios will offer the candidate exposure to clinical drug development and the potential to spend some time in Artios’s laboratories.

Beyond PARP-POLθ as an anticancer target. Science. 2018 Mar 16;359(6381):1217-1218. doi: 10.1126/science.aar5149. Higgins GS, Boulton SJ, Science. 2018 Mar 16;359(6381):1217-1218

A role for human homologous recombination factors in suppressing microhomology-mediated end joining. Ahrabi S, Sarkar S, Pfister SX, Pirovano G, Higgins GS, Porter AC, Humphrey TC. Nucleic Acids Res. 2016 Jul 8;44(12):5743-57.

A small interfering RNA screen of genes involved in DNA repair identifies tumor-specific radiosensitization by POLQ knockdown. Higgins GS, Prevo R, Lee YF, Helleday T, Muschel RJ, Taylor S, Yoshimura M, Hickson ID, Bernhard EJ, McKenna WG. Cancer Res. 2010 Apr 1;70(7):2984-9

Funding Notes

All complete applications received by 12 noon (UK time) on Friday 11 January 2020 will automatically be considered for all relevant competitive University and funding opportunities, including the Clarendon Fund, Medical Research Council funding, and various College funds. Please refer to the Funding and Costs webpage (View Website) for this course for further details relating to funded scholarships and divisional funding opportunities.

Funded studentships are highly competitive and are awarded to the highest ranked applicant(s) based on the advertised entry requirements for each programme of study.


Whilst you must register three referees, the department may start the assessment of your application if two of the three references are submitted by the course deadline and your application is otherwise complete. Please note that you may still be required to ensure your third referee supplies a reference for consideration.

Academic references are strongly encouraged, though you may use up to one professional reference provided that it is relevant to the course.

How good is research at University of Oxford in Clinical Medicine?

FTE Category A staff submitted: 238.51

Research output data provided by the Research Excellence Framework (REF)

Click here to see the results for all UK universities

Email Now

Insert previous message below for editing? 
You haven’t included a message. Providing a specific message means universities will take your enquiry more seriously and helps them provide the information you need.
Why not add a message here
* required field
Send a copy to me for my own records.

Your enquiry has been emailed successfully

FindAPhD. Copyright 2005-2019
All rights reserved.